Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1CNS 1

Conditions

Oligodendroglioma 1Neoplasms 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × LB100 × Clear all
NCT04560972 2026-04-07

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

City of Hope Medical Center

Phase 1 Active not recruiting
3 enrolled

Extensive Stage Lung Small Cell Carcinoma

NCT06012734 2024-08-30

CoLBAt

The Netherlands Cancer Institute

Phase 1 Recruiting
37 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03027388 2023-11-22

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
7 enrolled 20 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Lixte Biotechnology Holdings, Inc.

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡